Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Life SciencesNSE:SAILIFE +3.47%19 EV-to-EBITDA is 45.12 as of Aug. 21, 2026, which is 35% above its 10-year median of 33.38. GuruFocus rates NSE:SAILIFE with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Sai Life Sciences ranks worse than 86.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sai Life Sciences's enterprise value is ₹312,707 Mil.
Sai Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹6,930 Mil. Therefore, Sai Life Sciences's EV-to-EBITDA for today is 45.12.
The historical rank and industry rank for Sai Life Sciences's EV-to-EBITDA or its related term are showing as below:
NSE:SAILIFE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 26.18 Med: 33.38 Max: 45.12
Current: 45.12
During the past 5 years, the highest EV-to-EBITDA of Sai Life Sciences was 45.12. The lowest was 26.18. And the median was 33.38.
NSE:SAILIFE's EV-to-EBITDA is ranked worse than 86.32% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 17.13
vs NSE:SAILIFE: 45.12
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sai Life Sciences (NSE:SAILIFE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sai Life Sciences's PE Ratio (TTM) for today is calculated as:
Sai Life Sciences's share price for today is ₹1471.60.
Sai Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹16.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sai Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SAILIFE vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Sai Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Life Sciences EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sai Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sai Life Sciences's EV-to-EBITDA falls into.
Sai Life Sciences's current Enterprise Value is ₹312,707 Mil.
Sai Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,930 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Life Sciences (NSE:SAILIFE) has a EV-to-EBITDA of 45.12 as of Aug. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sai Life Sciences. This is 35% above median its historical median of 33.38. Over the past decade, Sai Life Sciences' EV-to-EBITDA has ranged from 26.18 to 45.12. According to the industry distribution chart, Sai Life Sciences ranks #101 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 86.3%.
Is Sai Life Sciences' EV-to-EBITDA too high?
Sai Life Sciences' current EV-to-EBITDA of 45.12 is 35% above median its 10-year median of 33.38. Over the past 10 years, this metric has ranged from a low of 26.18 to a high of 45.12. The Medical Diagnostics & Research industry median EV-to-EBITDA is 17.13. Sai Life Sciences' value of 45.12 is 163.4% above this industry median. Based on the distribution chart, Sai Life Sciences ranks #101 out of 117 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sai Life Sciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Sai Life Sciences' EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Sai Life Sciences ranks #101 out of 117 companies for EV-to-EBITDA. This places Sai Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 17.13. Sai Life Sciences' value of 45.12 is 163.4% above this benchmark. Historically, Sai Life Sciences' own EV-to-EBITDA has ranged from 26.18 to 45.12 over the past decade. While the company's 10-year median is 33.38 vs. the industry median of 17.13, Sai Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 17.13, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Life Sciences's current EV-to-EBITDA of 45.12 is 163.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sai Life Sciences. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 17.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Life Sciences's current EV-to-EBITDA is 45.12, which is 35% above median its own 10-year median of 33.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Life Sciences stock overvalued right now?
Sai Life Sciences (NSE:SAILIFE) has a current EV-to-EBITDA of 45.12. The current EV-to-EBITDA is 45.12, which is 35% above median its 10-year median of 33.38 and 163.4% above the Medical Diagnostics & Research industry median of 17.13. Sai Life Sciences' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sai Life Sciences (NSE:SAILIFE), the current EV-to-EBITDA is 45.12 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Life Sciences Ltd is an innovator-focused, contract research, development, and manufacturing organization. It provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule new chemical entities (NCE), to pharmaceutical innovator companies and biotechnology firms. It possesses both; discovery/contract research (CRO) and chemistry, manufacturing, and control (CMC)/contract development and manufacturing organization (CDMO) capabilities. The company has only one reportable segment: contract research, development, and manufacturing. Geographically it operates in India as well as Outside India.
19GF Score
Get the complete analysis for NSE:SAILIFE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAILIFE has been successfully added to your 
